Cargando…
Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
Urothelial carcinoma of the bladder (UCB) and upper tracts (UTUC) used to share management with similar principles. However, their genetic and epigenetic differences along with different responses to immunotherapy were recently identified, which are reminiscent of their distinct etiologies. Differen...
Autores principales: | Yang, Huang-Yu, Yang, Chih-Chao, Wu, Chao-Yi, Wang, Li-Jen, Lu, Kun-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650931/ https://www.ncbi.nlm.nih.gov/pubmed/31261684 http://dx.doi.org/10.3390/ijms20133162 |
Ejemplares similares
-
Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma
por: Boot, Arnoud, et al.
Publicado: (2020) -
Mutational signature and clonal relatedness of recurrent urothelial carcinomas with aristolochic acid
por: Zhu, Jie, et al.
Publicado: (2022) -
Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma
por: Jhuang, Jing-Rong, et al.
Publicado: (2023) -
Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway
por: Chen, I-Hsuan, et al.
Publicado: (2019) -
Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma
por: Lu, Huan, et al.
Publicado: (2020)